Kura Oncology, Inc.
KURA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001422143
In the last 90 days, Kura Oncology, Inc. insiders filed 2 open-market purchases and 3 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $953.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kura Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 2 filings
- 1 insider, $2.35M in total
- Open-market sells
- 3 filings
- 3 insiders, $673.9K in total
- Insiders trading
- 4
- Net value
- +$1.68M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kura Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Burrows Francis | Chief Scientific Officer | 42,327 | Sep 25, 2026 | 4 |
| Fulk Jennifer | Chief Financial Officer | – | Sep 10, 2026 | 1 |
| Wilson Troy Edward | President and CEO | 479,194Indirect | Aug 24, 2026 | 6 |
| Powl Brian T. | Chief Commercial Officer | 169,269 | Aug 24, 2026 | 7 |
| Bair Teresa Brophy | Chief Legal Officer | 195,444 | Aug 21, 2026 | 6 |
| Leoni Mollie | Chief Medical Officer | 182,345 | Jun 22, 2026 | 5 |
| Schafer Carol | Director | – | Jun 4, 2026 | 1 |
| Hasnain Faheem | Director | 23,983 | Jun 4, 2026 | 2 |
| Malley Thomas | Director | 10,000 | Jun 4, 2026 | 2 |
| Szela Mary T | Director | – | Jun 4, 2026 | 1 |
| Collins Helen Louise | Director | – | Jun 4, 2026 | 1 |
| Vasconcelles Michael | Director | – | Jun 4, 2026 | 1 |
| Parks Diane L. | Director | – | Jun 4, 2026 | 1 |
| Ford Kathleen | Chief Operating Officer | 153,560 | May 20, 2026 | 5 |
| Doyle Thomas James | SVP, Finance & Accounting | 145,167 | Jan 27, 2026 | 4 |
| Dale Stephen | Chief Medical Officer | 38,817 | Jan 31, 2024 | 0 |
| Flowers Kirsten | CCO & Chief Strategy Officer | 20,605 | Jan 31, 2023 | 0 |
| Stein Steven H | Director | – | Jun 23, 2022 | 0 |
| Grasso Marc | CFO, CBO | 21,900 | Jan 28, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Doyle Thomas JamesSVP, Finance & Accounting | SSale | −1.55K | $13.89 | −$21.5K | −8.4%16.8K after | 2 lots |
| Jan 31, 2023 (view filing) | Jan 27 | 4 days | Dale StephenChief Medical Officer | SSale | −9.22K | $13.88 | −$128.0K | −25.0%27.7K after | 2 lots |
| Nov 18, 2022 (view filing) | Nov 17 | 1 day | Bair Teresa BrophyChief Legal Officer | SSale | −2.10K | $15.22 | −$32.0K | −100.0%0 after |